Role of postoperative radiotherapy in the management for resected NSCLC - decision criteria in clinical routine pre- and post-lungART
Le Pechoux, C.
Putora, P. M.
De Ruysscher, D
Van Houtte, P.
Troost, E. G. C.
Slotman, B. J.
Peeters, S. T. H.
AffiliationDepartment of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland
MetadataShow full item record
AbstractBackground: The role of postoperative radiation therapy (PORT) in stage III N2 NSCLC is controversial. We analyzed decision-making for PORT among European radiation oncology experts in lung cancer. Methods: Twenty-two experts were asked before and after presentation of the results of the LungART trial to describe their decision criteria for PORT in the management of pN+ NSCLC patients. Treatment strategies were subsequently converted into decision trees and analyzed. Results: Following decision criteria were identified: extracapsular nodal extension, incomplete lymph node resection, multistation lymph nodes, high nodal tumor load, poor response to induction chemotherapy, ineligibility to receive adjuvant chemotherapy, performance status, resection margin, lung function and cardiopulmonary comorbidities. The LungART results had impact on decision-making and reduced the number of recommendations for PORT. The only clear indication for PORT was a R1/2 resection. Six experts out of ten who initially recommended PORT for all R0 resected pN2 patients no longer used PORT routinely for these patients, while four still recommended PORT for all patients with pN2. Fourteen experts used PORT only for patients with risk factors, compared to eleven before the presentation of the LungART trial. Four experts stated that PORT was never recommended in R0 resected pN2 patients regardless of risk factors. Conclusion: After presentation of the LungART trial results at ESMO 2020, 82% of our experts still used PORT for stage III pN2 NSCLC patients with risk factors. The recommendation for PORT decreased, especially for patients without risk factors. Cardiopulmonary comorbidities became more relevant in the decision-making for PORT.
CitationSüveg K, Le Pechoux C, Faivre-Finn C, Putora PM, De Ruysscher D, Widder J, et al. Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. Clinical Lung Cancer. 2021 Aug.
JournalClinical Lung Cancer
- Association between clinicopathological factors and postoperative radiotherapy in patients with completely resected pathological N2 non-small cell lung cancer.
- Authors: Xu Y, Li J, Wang J, Hu X, Ma H, Li P, Zheng X, Chen M
- Issue date: 2018 Feb
- Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
- Authors: Kim BH, Kim HJ, Wu HG, Kang CH, Kim YT, Lee SH, Kim DW
- Issue date: 2014 Sep
- Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes.
- Authors: Billiet C, De Ruysscher D, Peeters S, Decaluwé H, Vansteenkiste J, Dooms C, Deroose CM, De Leyn P, Hendrikx M, Bulens P, Le Péchoux C, Mebis J
- Issue date: 2016 Sep
- Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.
- Authors: Califano R, Karamouzis MV, Banerjee S, de Azambuja E, Guarneri V, Hutka M, Jordan K, Kamposioras K, Martinelli E, Corral J, Postel-Vinay S, Preusser M, Porcu L, Torri V
- Issue date: 2014 Jul
- Post-operative radiation therapy.
- Authors: Paumier A, Le Péchoux C
- Issue date: 2013 Oct